Tim Lowinger

Tim Lowinger

Company: Mersana Therapeutics

Job title: Chief Scientific & Technology Officer


Chairperson’s Opening Remarks 8:25 am

Read more

day: day 2- am

Beyond Cytotoxic ADCs & Immunogenic Cell Death: Advancing ADCs Fully Into Immuno-oncology 4:45 pm

Design and optimization of the Immunosynthen STING agonist ADC platform Extensive characterization of the pre-clinical profile of XMT-2056, a novel, Her-2 targeted Immunosynthen ADC Translational Research demonstrating the mechanism of an Immnosynthen ADC and its ability to activate the STING pathway in tumor cells and tumor-resident immune cells to deliver a “1-2 punch”Read more

day: day 1- pm

Industry Leaders’ Panel Discussion 8:15 am

Outlining the most exciting developments within the last 12 months Exploring what the current clinical and commercialization landscape looks like Sharing the biggest up and coming trends within the ADC field Examining the next big challenges ADC developers will faceRead more

day: day 1- am

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.